Philmans Pharm,, The German Patient Roundtable

Est. 1977



After two days of due diligence and consultation with our legal counsel, we have concluded that there are multiple laws in effect that are in conflict with the recent release from the DEA.

It is obvious that the DEA is continuing to come after the CBD market and it is most likely spurred by Big Pharma based on their desire to develop cannabinoid pharmaceuticals.

It should be noted that the proposed DEA rule is strictly a “Tracking Rule” and the rest of the rule is simply an interpretive rule. The DEA has a habit of overstepping their boundaries, as we have seen previously when they lost to the HIA.

Remember, the DEA is supposed to enforce the laws of our Great Land, not create them and the Farm Bill also defunded the DEA which should prevent them from interfering with any legal hemp business.

We expect clarification or redaction of this rule from the DEA prior to January 17, which is when it is to go in to effect.

Under its current form, it appears the DEA now views even hemp seed oil a Schedule 1 Drug, which we know would never hold up in court.

For now it is business as usual and we will continue to work with legal counsel and the entire industry to further develop clarity around this matter.

Have a great day,

Team Isodiol


Over the last 4 decades I have been involved in the fight for patient rights in America, and now here in Germany. During my career I have served as a Board of Director for the World Trade Center San Diego and as a Lead Consultant for Deutsche Telekom's Executive Board, Co-Founded the San Diego Software Council and the Dayton Human Trafficking Accords and was Director of LawInfo's Lead Council Program. Previously I was a C-Level Business Development Executive in the technology sector, but also involved with the cannabis industry since 1977. More recently I have been fulltime in the legal medical marijuana industry here in Europe, helping international companies navigate the biggest potential market in the world. This website is light on details due to confidentiality issues with clients but be rest assured I am knowledgeable, professional and with street cred in the industry that can immediately assist your growth in some way. Consulting Services: Sales and Business Development Assist with Strategic Direction Professionally represent your firm Special Projects management Licensing and compliance Sales and Distribution networks Qualify potential partners I am your resource on the ground in Europe, contact me directly to schedule an initial discussion on the German Cannabis-as-Medicine market. Thank you, Philip J. Cenedella IV Call +1.888.206.3264 USA + GERMANY Skype: philip.j.cenedella eMail: LinkedIN:

Comments are closed.